Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 422 | 5日内发货 | ||
5 mg | ¥ 690 | 5日内发货 | ||
10 mg | ¥ 987 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 948 | 5日内发货 |
Momelotinib sulfate 的其他形式现货产品:
产品描述 | Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3. |
靶点活性 | JAK2:18 nM, JAK1:11 nM, JAK3:155 nM |
体外活性 | Momelotinib sulfate inhibits growth of Ba/F3-JAK2V617F and Ba/F3-MPLW515L cells (IC50: 200 nM) or human erythroleukemia (HEL) cells (IC50: 1.5 μM). However, it has considerably less activity against BCR-ABL harboring K562 cells (IC50=58 μM) and FLT3 mutation harboring MV4-11 cells (IC50: 3 μM). Proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated with IL-3 is inhibited (IC50: 1.4 μM). This is same as the established role of IL-3-dependent signaling in the parental cell line [1]. |
体内活性 | Momelotinib sulfate at twice the dose used in disease model (50 and 100 mg/kg) has little to no effect on peripheral blood counts over a period of 8 weeks. Median plasma peak concentrations are 7.1 μM with the lower dose and 32.1μM with the higher dose, with a half-life of approximately 2 hours. Trough levels at 12 hours are 10nM for the 25 mg/kg and 900nM for the 50 mg/kg dose. After oral dosing, Momelotinib sulfate shows high plasma concentrations (Cmax= 40.4 μM; Tmax=4 h), with quantitative absolute oral bioavailability and an apparent half life of 2.4 h. The high oral bioavailability, can likely be partly ascribed to the low blood clearance of Momelotinib sulfate (6.3 mL/min/kg) and therefore low susceptibility to hepatic first pass metabolism [3]. At day 34 after transplantation, the mean white blood cell counts and hematocrit values of the entire cohort exceeded the normal range for Balb/c mice by more than 1 SD. At this point, 6 mice are sacrificed and subjected to autopsy. In the remaining animals, treatment is initiated with 25 mg/kg Momelotinib sulfate, 50 mg/kg Momelotinib sulfate, or vehicle, administered twice daily by oral gavage (12 mice per treatment group). A rapid drop of the white cell counts is apparent in both dose cohorts as early as 6 days after initiation of treatment and a decline of the hematocrit is apparent after 20 days [2]. |
别名 | CYT387 sulfate salt |
分子量 | 610.62 |
分子式 | C23H26N6O10S2 |
CAS No. | 1056636-06-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.2 mg/mL (10.15 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6377 mL | 8.1884 mL | 16.3768 mL | 40.942 mL |
5 mM | 0.3275 mL | 1.6377 mL | 3.2754 mL | 8.1884 mL | |
10 mM | 0.1638 mL | 0.8188 mL | 1.6377 mL | 4.0942 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Momelotinib sulfate 1056636-06-6 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK CYT387 sulfate salt Momelotinib Sulfate CYT387 Sulfate CYT 387 Sulfate CYT-387 Sulfate Inhibitor inhibitor inhibit